Eating disorders are on the rise. GLP-1s could make things worse.

GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…

一項全球估算顯示，1990至2023年神經性厭食症和神經性貪食症的發病率上升了71%，2023年約有1810萬人患病。臨床心理學家擔心，社交媒體、疫情隔離以及日益流行的GLP-1減肥藥正在加劇這一問題，部分患者甚至濫用這類藥物。